Mucosal delivery of nanovaccine strategy against COVID-19 and its variants

Lee, Junwoo; Khang, Dongwoo

doi:10.1016/j.apsb.2022.11.022

Search citation statements

Order By: Relevance

Paper Sections

Select...

Whole-virus Vaccines1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2023

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 230 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These candidates utilize different approaches. Interestingly, several candidates (Meissa Vaccines’ MV-014-212 and Codagenix’s COVI-VAC, specifically) are administered intranasally, potentially improving accessibility by eliminating the need for sterile needles and reducing manufacturing costs, targeting conferring mucosal immunity, and reducing some issues related to vaccine hesitancy ( 27 , 28 ). Additionally, although no phase III trial data are available for LAV candidates, some manufacturers have proactively sought to respond to the emergence of VOC.…”

Section: Whole-virus Vaccinesmentioning

confidence: 99%